Anonymised, illustrative composite. Most distressed succession sales run on tax and family dynamics, which a buyer can only guess at. This one ran on a licensing deadline printed in a statute, which the buyer could read as clearly as the executor could.
At a glance
A pharmacist who had operated for thirty-one years died holding two stores in two different ways. The older store he had never incorporated: he owned and operated it personally. The newer one, opened in 2011, sat in a corporation in which he held every share. His will named his sister — not a pharmacist — as estate trustee.
Fourteen months passed before a sale process began, taken up with probate, an interim management arrangement and a family disagreement about whether to sell at all. When the estate finally came to market, the buyer — a pharmacist-owned regional group — was the third party approached and the first to read the statute. See what happens when the owner dies before the sale closes for the general problem.
The estate's advisers had priced the two stores as one asset on one timeline. They are two assets on two timelines, because the deceased held them in two different capacities and the Drug and Pharmacies Regulation Act addresses each capacity in a different subsection.
For the personally-owned store, s.145(2) governs: “Upon the death of a pharmacist who was owning and operating a pharmacy at the time of his or her death, the personal representative of such deceased person may own and operate the pharmacy for a period of four years or for such further period as the Council may authorize.”
For the corporately-owned store, the relevant provision is not about owning the pharmacy at all — the corporation still owns it. It is about whether the corporation still satisfies the share test. Section 142(3) provides: “For the purposes of subsection (2), shares registered in the name of the personal representative of a deceased pharmacist shall, for a period not exceeding four years, be considered to be registered in the name of a pharmacist.”
Both say four years. They are not the same four years and they do not have the same flexibility.
Fourteen months had already gone. That left 34 months on both clocks when the process started. The estate asked $7,900,000 for the pair; the buyer opened at $6,400,000.
The negotiation turned on which clock mattered. On the personally-owned store the estate had a genuine argument that the deadline was soft, because s.145(2) contemplates a further period authorised by Council. On the corporate store it had no such argument on the face of the section: s.142(3) deems the representative's shares to be a pharmacist's holding for a period not exceeding four years, and says nothing about an extension. If the shares are not transferred to a pharmacist or a qualifying health profession corporation before that period runs, the corporation stops satisfying s.142(2), and under s.144(1) it is then not a person who may own or operate the pharmacy.
So the corporate store — the newer, busier, more valuable of the two — carried the harder deadline. The estate's asking price had assumed the opposite.
The lesson is a unit lesson. Section 145(2) governs who may own and operate a pharmacy where the deceased owned it personally. Section 142(3) governs whether shares in a corporation count towards a statutory majority. Same estate, same executor, same four-year period, entirely different subject matter — and the extension power sits in only one of them.
Section 145(3) then supplies the fact that made the deadline provable rather than merely arguable: “Every person authorized to own and operate a pharmacy under subsection (1) or (2) shall immediately upon becoming so authorized file with the Registrar evidence of the person's authority.” The estate had filed. The filing is dated. Both sides could establish when the clock started, which is unusual in a succession sale, where the seller's real deadline is normally private.
That is what made this negotiation different from an ordinary estate sale. The pressure was not inferred from the executor's tone or the family's circumstances. It was published, symmetrical and countable in months.
The pair sold for $7,050,000: $5,650,000 at closing and $1,400,000 deferred over 24 months, secured and subordinated to the buyer's bank. The discount to the asking price was almost entirely attributable to the corporate store, where the buyer priced the 34 remaining months against the cost and uncertainty of a second sale process if the first one failed.
One structural point mattered more than the price. The buyer took the corporate store by way of a share purchase from the estate — the buyer being a pharmacist-owned corporation holding a valid certificate of authorization, so the transfer put the shares straight back into a holder that satisfies s.142(2), and stopped the s.142(3) clock rather than merely running it down. The personally-owned store went as an asset purchase, with the buyer applying for its own certificate of accreditation in respect of those premises.
If the s.142(3) period had expired with the shares still registered to the personal representative, the corporation would have ceased to satisfy s.142(2) and, through s.144(1), would have been a person not permitted to own or operate the pharmacy. The estate's realistic alternatives at that point are a forced sale of a business that everyone knows must sell, or a wind-down of the more valuable of the two assets.
The executor's exposure is the ordinary one — a duty to the beneficiaries to realise the estate's assets sensibly — but the statutory deadline turns a general duty into a dated one.
The tell was the estate's own filing with the Registrar under s.145(3). Where a statute makes a personal representative file evidence of authority on a date, it has also created a public start date for every deadline that runs from it. In most succession sales a buyer is guessing about urgency. Here it could count.
The second tell was the shape of the holding itself — one store personal, one corporate. Two capacities means two regimes, and an adviser who prices them as one asset has not read past the first of the two subsections.
A 30-minute call is enough to tell you whether AI pays for itself here.
Canadian small-business transaction data is not published anywhere, so most valuations in this country quote an American benchmark. The Deavo–Treadstone Acquisition Index is a daily record of Canadian listings built to replace that: asking-price distributions by province and city are published now, and days on market, departure rates and asking-to-sale spreads follow as the series lengthens. Leave an email and we will tell you as each measure lands.
No pitch, no listings. One email when the first report lands.
